Peregrine Capital Management LLC Zymeworks Inc. Transaction History

Peregrine Capital Management LLC

  • $3.18 Billion
  • Q4 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 11, 2021
SELL
$29.83 - $56.81 $5.02 Million - $9.56 Million
-168,338 Closed
0 $0
Q4 2020

Jan 19, 2021
SELL
$39.12 - $54.99 $622,986 - $875,715
-15,925 Reduced 8.64%
168,338 $7.96 Million
Q3 2020

Oct 20, 2020
SELL
$29.21 - $46.58 $534,630 - $852,553
-18,303 Reduced 9.04%
184,263 $8.58 Million
Q2 2020

Jul 30, 2020
BUY
$33.67 - $40.0 $776,329 - $922,280
23,057 Added 12.84%
202,566 $7.31 Million
Q1 2020

Apr 17, 2020
BUY
$24.28 - $49.8 $4.36 Million - $8.94 Million
179,509 New
179,509 $6.37 Million

Others Institutions Holding ZYME

# of Institutions
1
Shares Held
296K
Call Options Held
0
Put Options Held
0
View Full List

About Zymeworks Inc.

ZYME Quotes by TradingView
  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $903M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Peregrine Capital Management LLC Portfolio

Follow Peregrine Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email